A5100774497- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Coronary Interventions and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac pacing and defibrillation studies
- Peripheral Artery Disease Management
- Lipoproteins and Cardiovascular Health
- Cardiac Imaging and Diagnostics
- Aortic Disease and Treatment Approaches
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Function and Risk Factors
- Pharmaceutical Economics and Policy
- Renal Diseases and Glomerulopathies
- Chronic Lymphocytic Leukemia Research
- Atrial Fibrillation Management and Outcomes
- Acute Myocardial Infarction Research
- Chronic Kidney Disease and Diabetes
- Acute Ischemic Stroke Management
- Renal and Vascular Pathologies
- Lymphoma Diagnosis and Treatment
- Intracranial Aneurysms: Treatment and Complications
- Blood Pressure and Hypertension Studies
- Venous Thromboembolism Diagnosis and Management
Saint Luke's Hospital
2014-2024
Therapeutics Clinical Research
2022-2024
Second Affiliated Hospital of Zhejiang University
2009-2023
University of Missouri–Kansas City
2009-2019
Brigham and Women's Hospital
2008-2017
Duke University
2017
Merck & Co., Inc., Rahway, NJ, USA (United States)
2017
Affiliated Zhongshan Hospital of Dalian University
2016
MedStar Washington Hospital Center
2016
Saint Luke's Health System
2012-2016
Despite limited evidence from randomized trials, perioperative treatment with beta-blockers is now widely advocated. We assessed the use of and their association in-hospital mortality in routine clinical practice.We conducted a retrospective cohort study patients 18 years age or older who underwent major noncardiac surgery 2000 2001 at 329 hospitals throughout United States. used propensity-score matching to adjust for differences between received those did not receive such therapy compared...
Background— In patients with severe aortic stenosis who cannot have surgery, transcatheter valve replacement (TAVR) has been shown to improve survival and quality of life compared standard therapy, but the costs cost-effectiveness this strategy are not yet known. Methods Results— The PARTNER trial randomized symptomatic, were candidates for surgery TAVR (n=179) or therapy (n=179). Empirical data regarding survival, life, medical resource use, hospital collected during used project...
Previous studies have shown that among patients undergoing multivessel revascularization, coronary-artery bypass grafting (CABG), as compared with percutaneous coronary intervention (PCI) either by means of balloon angioplasty or the use bare-metal stents, results in greater relief from angina and improved quality life. The effect PCI drug-eluting stents on these outcomes is unknown.
Background: In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment transcatheter valve replacement (TAVR) or (SAVR) results in similar rates of death stroke 2 years. Whether TAVR is cost-effective compared SAVR for intermediate-risk remains uncertain. Methods: Between 2011 and 2014, 3110 AS were treated the PARTNER trial (Placement Aortic Transcatheter Valves 2). A total 2032 randomized to receive using SAPIEN XT (XT-TAVR) 2A trial, whereas S3i registry...
Background— Peripheral artery disease (PAD) is common and imposes a high risk of major systemic limb ischemic events. The RE duction A therothrombosis for C ontinued H ealth (REACH) Registry an international prospective registry patients at atherothrombosis caused by established arterial or the presence ≥3 atherothrombotic factors. Methods Results— We compared 2-year rates vascular-related hospitalizations associated costs in US with PAD across patient subgroups. Symptomatic enrollment was...
Background— Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease leading death in industrialized world. The objectives present study are (1) to examine annual costs associated with vascular events interventions that require hospitalization, as well long-term medication use for management risk factors, a US population outpatients multiple atherothrombotic factors or history symptomatic (2) compare across patient subgroups defined...
In patients with acute coronary syndromes and planned percutaneous intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment prasugrel versus clopidogrel was associated reduced rates of cardiovascular death, MI, or stroke an increased risk major bleeding. We evaluated cost-effectiveness from perspective US healthcare system using data TRITON-TIMI...
Studies from the balloon angioplasty and bare metal stent eras have demonstrated that coronary artery bypass grafting (CABG) is cost-effective compared with percutaneous intervention (PCI) for patients undergoing multivessel revascularization-particularly among complex disease or diabetes mellitus. Whether these results apply in drug-eluting (DES) era unknown.
Background and Purpose— Clinical trials have demonstrated improved 90-day outcomes for patients with acute ischemic stroke treated stent retriever thrombectomy plus tissue-type plasminogen activator (SST+tPA) compared tPA. Previous studies suggested that this strategy may be cost-effective, but models were derived from pooled data older assumptions. Methods— In prospective economic substudy conducted alongside the SWIFT-PRIME trial (Solitaire With Intention Thrombectomy as Primary...
<h3>Importance</h3> In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment transcatheter valve replacement (TAVR) or (SAVR) results in similar 2-year survival. The effect of TAVR vs SAVR on health status risk is unknown. <h3>Objective</h3> To compare health-related quality life among intermediate-risk AS treated either SAVR. <h3>Design, Setting, and Participants</h3> Between December 2011 November 2013, 2032 were randomized to the Sapien XT Placement Aortic...
Background— The Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial demonstrated that in patients with 3-vessel or left main coronary artery disease, bypass graft surgery (CABG) was associated a lower rate of cardiovascular death, myocardial infarction, stroke, repeat revascularization compared percutaneous drug-eluting stents (DES-PCI)). long-term cost-effectiveness these strategies is unknown. Methods Results— 2005 2007, 1800 disease were...
The COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with resulted in reduced mortality and heart failure hospitalizations improved quality life compared maximally tolerated guideline-directed medical therapy (GDMT) patients 3 to 4+ secondary regurgitation. Whether TMVr is cost-effective GDMT this population unknown. We...
Background: In patients with severe symptomatic aortic stenosis at low surgical risk, transfemoral transcatheter valve replacement (TAVR) the SAPIEN 3 has been shown to reduce composite of death, stroke, or rehospitalization 2-year follow-up compared (SAVR). Whether TAVR is cost-effective SAVR for low-risk remains uncertain. Methods: Between 2016 and 2017, 1000 were randomly assigned in PARTNER trial (Placement Aortic Transcatheter Valves). Of these patients, 929 underwent replacement,...
Background— Elevated serum cholesterol accounts for a considerable proportion of cardiovascular disease worldwide. An understanding the relationship between country-level economic and health system factors elevated may provide insight prioritization prevention programs. Methods Results— Using hierarchical models, we examined total (>200 mg/dL) in 53 570 outpatients from 36 countries, tertiles several indices: (1) gross national income, (2) expenditure on as percentage domestic product,...
IgA nephropathy (IgAN) is a progressive autoimmune kidney disease and leading cause of glomerular that can result in failure (KF). The median age at diagnosis 35 to 37 years approximately 50% patients will progress KF within 20 years. We aimed enhance the understanding renal histology chronic (CKD) stage time IgAN using large real-world biopsy cohort.This retrospective cohort study evaluated data clinical characteristics from adult US who were diagnosed with between January 1, 2016 May 31,...
Background Transcatheter edge-to-edge mitral valve repair (TMVr) improves symptoms and survival for patients with heart failure reduced left ventricular ejection fraction (HFrEF) severe secondary regurgitation despite guideline-recommended medical therapy (GRMT). Whether TMVr is cost-effective from a UK National Health Service (NHS) perspective unknown. Methods We used patient-level data the Cardiovascular Outcomes Assessment of MitraClip Percutaneous Therapy Heart Failure Patients...